ASX - By Stock
|
TLX |
Re:
How low will it go?
|
|
89zirconium
|
132 |
59K |
3 |
15/05/22 |
15/05/22 |
ASX - By Stock
|
132
|
59K
|
3
|
|
ASX - By Stock
|
TLX |
Re:
My analysis and intrinsic value of TLX March 2022
|
|
89zirconium
|
82 |
42K |
1 |
11/05/22 |
11/05/22 |
ASX - By Stock
|
82
|
42K
|
1
|
|
ASX - By Stock
|
TLX |
Re:
My analysis and intrinsic value of TLX March 2022
|
|
89zirconium
|
82 |
42K |
2 |
09/05/22 |
09/05/22 |
ASX - By Stock
|
82
|
42K
|
2
|
|
ASX - By Stock
|
TLX |
Re:
My analysis and intrinsic value of TLX March 2022
|
|
89zirconium
|
82 |
42K |
0 |
06/05/22 |
06/05/22 |
ASX - By Stock
|
82
|
42K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
My analysis and intrinsic value of TLX March 2022
|
|
89zirconium
|
82 |
42K |
0 |
06/05/22 |
06/05/22 |
ASX - By Stock
|
82
|
42K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
My analysis and intrinsic value of TLX March 2022
|
|
89zirconium
|
82 |
42K |
0 |
06/05/22 |
06/05/22 |
ASX - By Stock
|
82
|
42K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
My analysis and intrinsic value of TLX March 2022
|
|
89zirconium
|
82 |
42K |
0 |
06/05/22 |
06/05/22 |
ASX - By Stock
|
82
|
42K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
Shorters discover Telix
|
|
89zirconium
|
234 |
85K |
0 |
06/05/22 |
06/05/22 |
ASX - By Stock
|
234
|
85K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
Shorters discover Telix
|
|
89zirconium
|
234 |
85K |
0 |
06/05/22 |
06/05/22 |
ASX - By Stock
|
234
|
85K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
Approval
|
|
89zirconium
|
48 |
18K |
0 |
06/05/22 |
06/05/22 |
ASX - By Stock
|
48
|
18K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
Is a $2,131,889,198.56 market cap justified
|
|
89zirconium
|
48 |
21K |
0 |
04/05/22 |
04/05/22 |
ASX - By Stock
|
48
|
21K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
Is a $2,131,889,198.56 market cap justified
|
|
89zirconium
|
48 |
21K |
0 |
04/05/22 |
04/05/22 |
ASX - By Stock
|
48
|
21K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
Is a $2,131,889,198.56 market cap justified
|
|
89zirconium
|
48 |
21K |
0 |
04/05/22 |
04/05/22 |
ASX - By Stock
|
48
|
21K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
My analysis and intrinsic value of TLX March 2022
|
|
89zirconium
|
82 |
42K |
0 |
04/05/22 |
04/05/22 |
ASX - By Stock
|
82
|
42K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
My analysis and intrinsic value of TLX March 2022
|
|
89zirconium
|
82 |
42K |
0 |
04/05/22 |
04/05/22 |
ASX - By Stock
|
82
|
42K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
My analysis and intrinsic value of TLX March 2022
|
|
89zirconium
|
82 |
42K |
0 |
04/05/22 |
04/05/22 |
ASX - By Stock
|
82
|
42K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
My analysis and intrinsic value of TLX March 2022
|
|
89zirconium
|
82 |
42K |
0 |
04/05/22 |
04/05/22 |
ASX - By Stock
|
82
|
42K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
My analysis and intrinsic value of TLX March 2022
|
|
89zirconium
|
82 |
42K |
0 |
04/05/22 |
04/05/22 |
ASX - By Stock
|
82
|
42K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
My analysis and intrinsic value of TLX March 2022
|
|
89zirconium
|
82 |
42K |
0 |
04/05/22 |
04/05/22 |
ASX - By Stock
|
82
|
42K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
Is a $2,131,889,198.56 market cap justified
|
|
89zirconium
|
48 |
21K |
0 |
03/05/22 |
03/05/22 |
ASX - By Stock
|
48
|
21K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
Ann: ZIRCON Phase 3 Renal Cancer Imaging Study - Progress Update
|
|
89zirconium
|
11 |
5.5K |
0 |
03/05/22 |
03/05/22 |
ASX - By Stock
|
11
|
5.5K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
Is a $2,131,889,198.56 market cap justified
|
|
89zirconium
|
48 |
21K |
0 |
03/05/22 |
03/05/22 |
ASX - By Stock
|
48
|
21K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
Is a $2,131,889,198.56 market cap justified
|
|
89zirconium
|
48 |
21K |
0 |
03/05/22 |
03/05/22 |
ASX - By Stock
|
48
|
21K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
Is a $2,131,889,198.56 market cap justified
|
|
89zirconium
|
48 |
21K |
0 |
03/05/22 |
03/05/22 |
ASX - By Stock
|
48
|
21K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
Is a $2,131,889,198.56 market cap justified
|
|
89zirconium
|
48 |
21K |
1 |
03/05/22 |
03/05/22 |
ASX - By Stock
|
48
|
21K
|
1
|
|
ASX - By Stock
|
TLX |
Re:
Is a $2,131,889,198.56 market cap justified
|
|
89zirconium
|
48 |
21K |
0 |
02/05/22 |
02/05/22 |
ASX - By Stock
|
48
|
21K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
Is a $2,131,889,198.56 market cap justified
|
|
89zirconium
|
48 |
21K |
0 |
02/05/22 |
02/05/22 |
ASX - By Stock
|
48
|
21K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
Is a $2,131,889,198.56 market cap justified
|
|
89zirconium
|
48 |
21K |
0 |
02/05/22 |
02/05/22 |
ASX - By Stock
|
48
|
21K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
Approval
|
|
89zirconium
|
48 |
18K |
0 |
02/05/22 |
02/05/22 |
ASX - By Stock
|
48
|
18K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
Is a $2,131,889,198.56 market cap justified
|
|
89zirconium
|
48 |
21K |
2 |
02/05/22 |
02/05/22 |
ASX - By Stock
|
48
|
21K
|
2
|
|
ASX - By Stock
|
TLX |
Re:
Is a $2,131,889,198.56 market cap justified
|
|
89zirconium
|
48 |
21K |
2 |
02/05/22 |
02/05/22 |
ASX - By Stock
|
48
|
21K
|
2
|
|
ASX - By Stock
|
TLX |
Re:
How low will it go?
|
|
89zirconium
|
132 |
59K |
2 |
01/05/22 |
01/05/22 |
ASX - By Stock
|
132
|
59K
|
2
|
|
ASX - By Stock
|
TLX |
Re:
Is a $2,131,889,198.56 market cap justified
|
|
89zirconium
|
48 |
21K |
2 |
30/04/22 |
30/04/22 |
ASX - By Stock
|
48
|
21K
|
2
|
|
ASX - By Stock
|
TLX |
Re:
Is a $2,131,889,198.56 market cap justified
|
|
89zirconium
|
48 |
21K |
1 |
29/04/22 |
29/04/22 |
ASX - By Stock
|
48
|
21K
|
1
|
|
ASX - By Stock
|
TLX |
Re:
Approval
|
|
89zirconium
|
48 |
18K |
0 |
29/04/22 |
29/04/22 |
ASX - By Stock
|
48
|
18K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
Ann: ZIRCON Phase 3 Renal Cancer Imaging Study - Progress Update
|
|
89zirconium
|
11 |
5.5K |
0 |
29/04/22 |
29/04/22 |
ASX - By Stock
|
11
|
5.5K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
Approval
|
|
89zirconium
|
48 |
18K |
0 |
29/04/22 |
29/04/22 |
ASX - By Stock
|
48
|
18K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
Approval
|
|
89zirconium
|
48 |
18K |
0 |
29/04/22 |
29/04/22 |
ASX - By Stock
|
48
|
18K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
Approval
|
|
89zirconium
|
48 |
18K |
1 |
29/04/22 |
29/04/22 |
ASX - By Stock
|
48
|
18K
|
1
|
|
ASX - By Stock
|
TLX |
Re:
Approval
|
|
89zirconium
|
48 |
18K |
0 |
29/04/22 |
29/04/22 |
ASX - By Stock
|
48
|
18K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
Approval
|
|
89zirconium
|
48 |
18K |
0 |
29/04/22 |
29/04/22 |
ASX - By Stock
|
48
|
18K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
Approval
|
|
89zirconium
|
48 |
18K |
0 |
29/04/22 |
29/04/22 |
ASX - By Stock
|
48
|
18K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
Ann: Appendix 3Y - Change in Directors Interests - O Buck
|
|
89zirconium
|
14 |
5.0K |
1 |
29/04/22 |
29/04/22 |
ASX - By Stock
|
14
|
5.0K
|
1
|
|
ASX - By Stock
|
TLX |
Re:
Approval
|
|
89zirconium
|
48 |
18K |
0 |
29/04/22 |
29/04/22 |
ASX - By Stock
|
48
|
18K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
Approval
|
|
89zirconium
|
48 |
18K |
2 |
29/04/22 |
29/04/22 |
ASX - By Stock
|
48
|
18K
|
2
|
|
ASX - By Stock
|
TLX |
Re:
Ann: ZIRCON Phase 3 Renal Cancer Imaging Study - Progress Update
|
|
89zirconium
|
11 |
5.5K |
1 |
29/04/22 |
29/04/22 |
ASX - By Stock
|
11
|
5.5K
|
1
|
|
ASX - By Stock
|
TLX |
Re:
Approval
|
|
89zirconium
|
48 |
18K |
1 |
28/04/22 |
28/04/22 |
ASX - By Stock
|
48
|
18K
|
1
|
|
ASX - By Stock
|
TLX |
Re:
Approval
|
|
89zirconium
|
48 |
18K |
1 |
28/04/22 |
28/04/22 |
ASX - By Stock
|
48
|
18K
|
1
|
|
ASX - By Stock
|
TLX |
Re:
Approval
|
|
89zirconium
|
48 |
18K |
1 |
28/04/22 |
28/04/22 |
ASX - By Stock
|
48
|
18K
|
1
|
|
ASX - By Stock
|
TLX |
Re:
Approval
|
|
89zirconium
|
48 |
18K |
1 |
28/04/22 |
28/04/22 |
ASX - By Stock
|
48
|
18K
|
1
|
|